This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wils, J.A. Articles by Coombes, R.C. Search for Related Content PubMed PubMed Citation Articles by Wils, J.A. Articles by Coombes, R.C. Social Bookmarking                            What's this?

Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group

From the Laurentius Hospital, Roermond, the Netherlands; The Institute of Cancer Research, Sutton, and the Department of Medical Oncology and ICCG Data Centre, Charing Cross Hospital, London, United Kingdom; Hôpital St Louis, Paris, and Center Hospitalier René Dubos, Pontoise, France; Akademisch Ziekenhuis Vrije Universiteit Brussel, Brussels, Belgium; Instituto Valenciano de Oncologia, Valencia, and Hospital Clinico Universitario, Zaragoza, Spain; and St Savvas Hospital, Athens, Greece.

Address reprint requests to J.M. Bliss, c/o, ICCG Data Centre, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom W6 8RF.

PURPOSE: To assess whether the addition of epirubicin (EPI) therapy to prolonged treatment with tamoxifen (TAM) improves relapse-free and overall survival in postmenopausal women with node-positive primary breast cancer.

PATIENTS AND METHODS: Six hundred four patients entered onto a randomized clinical trial were allocated to receive TAM 20 mg/d for 4 years or TAM 20 mg/d for 4 years plus EPI 50 mg/m² intravenously on days 1 and 8 every 4 weeks for six cycles. Analysis was performed according to allocated treatment, with all randomized patients included (intention to treat), irrespective of eligibility status.

RESULTS: After a median follow-up period of 5.7 years, an improvement in relapse-free survival (RFS) was observed for the TAM and EPI–treated patients, compared with those who received TAM alone. The unadjusted hazard ratio was 0.72 (95% confidence interval, 0.54 to 0.96), with a corresponding reduction in the odds of recurrence of 27.9% (SD, 12.3), which was statistically significant (P = .023). Adjustment for prognostic and/or predictive factors did not materially affect the hazard ratio. No difference was observed in terms of overall survival (reduction in odds of death, 11.9% [SD, 16.3]; P = .46). Combined chemohormonal treatment was associated with a higher incidence of acute side effects but without a clear increase in long-term cardiotoxicity. Twelve nonbreast second malignancies, including five hematologic malignancies (two of which were cases of acute myelogenous leukemia), were observed.

CONCLUSION: The data show that combined chemohormonal treatment reduces the risk of relapse in postmenopausal patients with node-positive breast cancer. No evidence was found, however, for an improvement in overall survival. The size of benefit observed for both outcomes was consistent with that reported in the Early Breast Cancer Trialists' Collaborative Group overview. The trial presented here, however, provides the first report of an improvement in RFS associated with the provision of a single cytotoxic drug in addition to prolonged TAM.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]

				G. Freyer, A.-C. Braud, P. Chaibi, M. Spielmann, J.-P. Martin, G. Vilela, D. Guerin, and L. Zelek Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients' Ann. Onc., February 1, 2006; 17(2): 211 - 216. [Abstract] [Full Text] [PDF]

				M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist, February 1, 2006; 11(2): 111 - 125. [Abstract] [Full Text] [PDF]

				M. Namer, P. Fargeot, H. Roche, M. Campone, P. Kerbrat, P. Romestaing, A. Monnier, E. Luporsi, P. Montcuquet, J. Bonneterre, et al. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials Ann. Onc., January 1, 2006; 17(1): 65 - 73. [Abstract] [Full Text] [PDF]

				S. Gluck Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin Oncologist, November 1, 2005; 10(10): 780 - 791. [Abstract] [Full Text] [PDF]

				L. Balducci Squaring the Circle: Adjuvant Chemotherapy for Older Women With Breast Cancer J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2005; 60(9): 1135 - 1136. [Full Text] [PDF]

				M. Campone, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group Ann. Onc., August 1, 2005; 16(8): 1343 - 1351. [Abstract] [Full Text] [PDF]

				C. Praga, J. Bergh, J. Bliss, J. Bonneterre, B. Cesana, R. C. Coombes, P. Fargeot, A. Folin, P. Fumoleau, R. Giuliani, et al. Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide J. Clin. Oncol., June 20, 2005; 23(18): 4179 - 4191. [Abstract] [Full Text] [PDF]

				M. Colleoni, S. Li, R. D. Gelber, A. S. Coates, M. Castiglione-Gertsch, K. N. Price, J. Lindtner, C.-M. Rudenstam, D. Crivellari, J. Collins, et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Ann. Onc., May 1, 2005; 16(5): 716 - 725. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Ann. Onc., December 1, 2004; 15(12): 1749 - 1759. [Abstract] [Full Text] [PDF]

				P. Fargeot, J. Bonneterre, H. Roche, A. Lortholary, M. Campone, I. Van Praagh, A. Monnier, M. Namer, S. Schraub, J.-C. Barats, et al. Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial J. Clin. Oncol., December 1, 2004; 22(23): 4674 - 4682. [Abstract] [Full Text] [PDF]

				J. Bonneterre, H. Roche, P. Kerbrat, P. Fumoleau, M.-J. Goudier, P. Fargeot, P. Montcuquet, P. Clavere, J.-C. Barats, A. Monnier, et al. Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group J. Clin. Oncol., August 1, 2004; 22(15): 3070 - 3079. [Abstract] [Full Text] [PDF]

				V. Cocquyt, K. Moeremans, L. Annemans, P. Clarys, and S. Van Belle Long-term medical costs of postmenopausal breast cancer therapy Ann. Onc., July 1, 2003; 14(7): 1057 - 1063. [Abstract] [Full Text] [PDF]

				M.-C. Le Deley, T. Leblanc, A. Shamsaldin, M.-A. Raquin, B. Lacour, D. Sommelet, A. Chompret, J.-M. Cayuela, C. Bayle, A. Bernheim, et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Societe Francaise d'Oncologie Pediatrique J. Clin. Oncol., March 15, 2003; 21(6): 1074 - 1081. [Abstract] [Full Text] [PDF]

				C. Hudis Breast Cancer and Leukemia: The Forest for the Trees? Ann. Surg. Oncol., October 1, 2002; 9(8): 717 - 718. [Full Text] [PDF]

				R. Arriagada, M. Spielmann, S. Koscielny, T. Le Chevalier, T. Delozier, M. Ducourtieux, T. Tursz, and C. Hill Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen Ann. Onc., September 1, 2002; 13(9): 1378 - 1386. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group (IBCSG) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial J Natl Cancer Inst, July 17, 2002; 94(14): 1054 - 1065. [Abstract] [Full Text] [PDF]

				D. Ginsburg Chemotherapy for older women with node-positive breast cancer Can. Med. Assoc. J., September 1, 2001; 165(5): 525 - 527. [Full Text]